^
    1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Jan 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer | Trial primary completion date: May 2026 --> Aug 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933